Rheumatoid arthritis (RA) is an immunologically and clinically heterogeneous disease with substantial variability in therapeutic response. This narrative review used a structured literature search covering studies from January 2000 through mid‑2026 to evaluate biomarkers of treatment response. Rather than listing markers by platform or drug class, the review integrates conventional biomarkers (rheumatoid factor, ACPA, CRP/ESR, calprotectin), pharmacological measures (drug concentrations, anti-drug antibodies), imaging, multi-omics, and synovial tissue immunophenotypes within a tissue-centered framework. Synovial pathotypes and cell‑type–specific signatures identified by single-cell and spatial omics provide mechanistic insight into response and resistance. The authors conclude that precision medicine in RA will require combined clinical, pharmacological, molecular, and synovial tissue data and call for validated, scalable models that assign synovial endotypes to guide mechanism-based therapy selection.
Rheumatoid arthritis is a chronic systemic immune-mediated inflammatory disease characterized by persistent synovitis, progressive joint destruction, and systemic manifestations. It affects roughly 0.5–1% of adults in industrialized countries and is more frequent in women. RA is molecularly heterogeneous: synovial tissue and peripheral blood profiling reveal variability in gene expression, immune cell composition, and cytokine networks.
Gene-expression studies have described distinct synovial pathotypes—lympho-myeloid, diffuse-myeloid, and pauci-immune/fibroblastic—each with different cellular compositions and inflammatory programs. Advances in single-cell and spatial transcriptomics have revealed diverse T cells, B cells, macrophage and fibroblast subsets that contribute to inflammation and tissue damage. These differences have direct clinical consequences because response to csDMARDs, biologics, or targeted synthetic DMARDs varies across patients.
Current treatment typically begins with conventional synthetic DMARDs with methotrexate as the anchor, escalating to biologic or targeted therapies (TNF inhibitors, IL-6 blockade, anti-CD20, co-stimulation blockers, JAK inhibitors) when needed. Despite multiple options, approximately 30–40% of patients do not respond adequately to first-line methotrexate and substantial proportions show insufficient or lost response to biologics. Treatment selection remains largely empirical, highlighting the unmet need for predictive biomarkers to guide therapy and reduce delays to disease control.
The review conducted a structured literature search between January 2026 and May 2026, with a final update on 15 June 2026. Databases searched included PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, supplemented by manual screening of reference lists. Search terms combined rheumatoid arthritis, biomarkers, treatment response, drug names (methotrexate, TNF inhibitors, rituximab, tocilizumab, abatacept, JAK inhibitors), synovial tissue, single-cell and spatial transcriptomics, and immune-repertoire analyses.
Inclusion criteria covered studies that investigated biomarkers associated with therapeutic response, resistance, disease activity, or prognosis in RA; evaluated csDMARDs, biologic DMARDs, or targeted synthetic DMARDs; and provided mechanistic insight, tissue-based or high-resolution molecular data. Priority was given to meta-analyses, systematic reviews, prospective cohorts, randomized trials, and large multicenter studies. The review was narrative but followed PRISMA-informed principles for transparency.
Biomarkers are categorized by clinical function into prognostic and predictive classes. Prognostic biomarkers inform expected disease course independent of treatment (for example, markers associated with structural progression). Predictive biomarkers estimate the likelihood of response to a specific therapy and often reflect activity in the pathway targeted by that therapy (for example, TNF-driven inflammation vs B-cell–mediated autoimmunity).
Further subclassification includes clinical biomarkers, pharmacological biomarkers, molecular biomarkers, and imaging biomarkers. For clinical use, biomarkers must be standardized, reproducible, validated, and actionable so that their measurement can inform treatment selection, dosing, or safety monitoring. The review aligns these concepts with regulatory frameworks such as the FDA–NIH BEST resource and common EMA classifications.
Clinical biomarkers are routinely available measures that quantify inflammatory burden and functional impact. Joint counts, patient global assessments, and composite indices such as DAS28 remain widely used. These composite indices integrate tender and swollen joint counts with inflammatory markers (ESR or CRP) and patient-reported measures. However, joint counts have limitations: reproducibility can be limited, subclinical inflammation may be missed, and extra-articular manifestations or comorbidities (for example, fibromyalgia) can confound assessment.
Established serological biomarkers include rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), which are prognostically and diagnostically useful but provide an incomplete view of mechanism-specific therapeutic response. Acute-phase reactants such as ESR and CRP are practical for monitoring systemic inflammation but do not fully capture synovial cellular circuits.
Composite disease activity scores (for example DAS28) are standard for clinical monitoring and decision-making but have recognized limitations for predicting treatment-specific response. While elevated systemic inflammatory markers correlate with overall disease activity, they do not necessarily indicate which pathogenic pathway predominates within the synovial microenvironment. Thus, reliance on conventional indices alone may be insufficient for mechanism-based therapeutic selection.
Pharmacological biomarkers include drug concentration monitoring and detection of anti-drug antibodies. These remain clinically useful measures of exposure and immunogenicity but do not explain all instances of primary or secondary nonresponse. The review emphasizes that drug-specific markers must be integrated with molecular and tissue-level data to clarify mechanisms of resistance and guide switching between therapies.
Emerging molecular biomarkers—derived from single-cell transcriptomics, spatial proteomics, immune-repertoire sequencing, and ligand–receptor interaction mapping—offer more direct links between cellular states in the synovium and response to drugs targeting specific pathways. Examples highlighted in the review include fibroblast and macrophage subsets, B-cell niches and tertiary lymphoid structures, and synovial expression programs aligned with therapeutic targets.
The authors stress translational readiness as a key requirement: biomarkers need external validation, standardization, and demonstration of clinical actionability. Tissue-based assays (for example, synovial histology, molecular endotyping) provide mechanistic depth but face practical barriers such as feasibility, cost, and the need for scalable assays. The review discusses evidence grading and translational readiness frameworks (summarized in tables) to prioritize markers that are reproducible and likely to change management.
Integrated panels combining clinical data, pharmacological monitoring, circulating molecular markers, imaging, and synovial tissue immunophenotyping are presented as the most promising route to implement mechanism-based treatment selection. Machine-learning and predictive models may aid interpretation, but require external validation and clinical interpretability.
Key future directions include development of scalable, externally validated models that can assign synovial endotypes and inform mechanism-based drug choice. Continued expansion and validation of single-cell and spatial omic signatures, immune‑repertoire analyses, and ligand–receptor network mapping are needed. The authors call for prospective studies that test integrated biomarker panels and demonstrate improved patient outcomes and cost-effectiveness compared with empirical treatment strategies.
Conventional serological and pharmacological biomarkers remain clinically useful but are insufficient to fully explain mechanism-specific responses in RA. High-resolution tissue immunophenotyping and multi-omic profiling reveal synovial endotypes and cellular circuits that better align with targeted therapies. Precision medicine in RA will likely require integrated biomarker panels combining clinical, pharmacological, molecular, and synovial tissue data, alongside validated, interpretable predictive models able to guide mechanism-based therapeutic selection.